RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5.0 (5)
  • Medicine

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. 1d ago

    FAQ: How Do Clinical Manifestations and Histopathologic Features Vary Across Myositis Subtypes?

    In this rheumatology FAQ, Audrey Gibson, PA-C, reviews how clinical manifestations and histopathologic features vary across idiopathic inflammatory myopathy subtypes, including dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, and inclusion body myositis. This clinically focused discussion highlights the key differences in muscle weakness patterns, skin findings, interstitial lung disease, malignancy risk, autoantibody associations, and muscle biopsy findings that help guide diagnosis, prognosis, monitoring, and treatment decisions. Audrey also explores hallmark histopathologic features such as perifascicular atrophy, endomysial inflammation, perimysial pathology, muscle fiber necrosis, rimmed vacuoles, and inclusion bodies. Designed for rheumatology advanced practice providers and clinicians, this FAQ offers practical insights to support earlier recognition, subtype-specific evaluation, multidisciplinary care, and more personalized management of patients with inflammatory myopathies.

  2. Jul 21

    FAQ: What Are the Key Unmet Needs in the Treatment of Idiopathic Inflammatory Myopathies?

    In this rheumatology FAQ, host Audrey Gibson, PA-C from the Arthritis Center of North Georgia in Gainesville, Georgia, discusses the key unmet needs in the treatment of idiopathic inflammatory myopathies, including myositis, dermatomyositis, immune-mediated necrotizing myopathy, and other rare inflammatory muscle diseases. These complex, heterogeneous autoimmune conditions can be difficult to diagnose and manage, often leading to delayed diagnosis, ongoing muscle weakness, disability, treatment toxicity, and gaps in long-term disease control. This episode explores why earlier recognition, better biomarkers, improved risk stratification, standardized treatment algorithms, steroid-sparing therapies, and more targeted treatment options are urgently needed in myositis care. Audrey also reviews how antibody profiles, such as anti-Mi-2, anti-SRP, and anti-MDA5, can influence prognosis and treatment decisions, while highlighting emerging therapeutic approaches including IVIG, rituximab, mycophenolate, JAK inhibitors, FcRn inhibitors, interferon pathway inhibition, and complement-targeted therapies. Designed for rheumatology advanced practice providers and clinicians caring for patients with autoimmune muscle disease, this discussion emphasizes the important role APPs play in identifying subtle disease progression, coordinating multidisciplinary care, monitoring medication toxicity, educating patients, and translating evolving myositis research into practical patient care. For more rheumatology education and clinical resources, visit the RhAPP content rheum, RhAPP ACE app, or RhAPP website.

  3. Jul 13

    RhAPPcast: Switch, Don’t Cycle: Interpreting the SELECT-SWITCH Trial and What It Means for RA Care

    Stay up to date with the latest advances in rheumatoid arthritis management in this RhAPPcast Fireside Chat episode focused on the SELECT-SWITCH trial and its implications for clinical practice. Hosted by Amanda Mixon, PA-C, this discussion features expert perspectives from Jeannette Hart, PA-C, and James Levine, DO, as they explore treatment decision-making after TNF inhibitor failure and what the latest evidence means for patients with rheumatoid arthritis. Learn why the SELECT-SWITCH trial was designed, how it compares switching to a different mechanism of action versus cycling within the TNF inhibitor class, and what the study revealed about efficacy, remission rates, and low disease activity outcomes. The panel discusses real-world considerations when selecting next-line therapies, including the role of JAK inhibitors such as upadacitinib, patient characteristics that may influence treatment choices, and how current guidelines support switching mechanisms after inadequate TNF inhibitor response. Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional managing patients with rheumatoid arthritis, this episode provides practical insights into interpreting clinical trial data, discussing treatment changes with patients, and balancing efficacy and safety when making therapeutic decisions. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.

  4. Jul 9

    RhAPPcast: Applying SLE Treatment Principles in Everyday Practice

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Heather Finlayson, PA-C, to discuss treat-to-target strategies in lupus management and how DORIS remission can be applied in real-world clinical practice. This conversation explores what successful lupus care looks like beyond flare management, including steroid minimization, low disease activity, shared decision-making, and the use of objective tools such as SLEDAI-2K to monitor disease activity. Listeners will gain practical insights on setting realistic remission goals, reducing long-term prednisone burden, recognizing when to escalate therapy, and helping patients understand that remission in systemic lupus erythematosus means stable disease control on therapy. Designed for rheumatology APPs and clinicians, this episode offers actionable strategies to improve lupus outcomes, support patient-centered care, and bring treat-to-target goals into everyday practice.

  5. Jul 7

    RhAPPcast: Pharmacists in Rheumatology

    In this episode of RhAPPcast, the official podcast of the Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by rheumatology pharmacist expert Danielle Gatti Palumbo, PharmD, to explore the expanding role of clinical pharmacists in rheumatology care. This conversation highlights how pharmacists are integrated into multidisciplinary teams to support the management of complex rheumatic diseases through medication optimization, side effect management, patient counseling, and improving access to therapies. Listeners will gain practical insights into key areas where pharmacists add value, including navigating complex dosing regimens, managing biologics and biosimilars, monitoring labs and safety parameters, and overcoming insurance and prior authorization barriers. The discussion also emphasizes real-world challenges such as patient adherence, therapy switching, and coordination between providers, pharmacies, and patients. Additionally, this episode underscores the importance of pharmacist-led patient education, shared decision-making, and proactive follow-up to enhance outcomes and reduce gaps in care. Ideal for rheumatology providers, pharmacists, and advanced practice providers, this episode delivers actionable strategies to improve efficiency, safety, and collaboration in clinical practice. For more expert-led rheumatology education, visit the RhAPP Content Rheum and RhAPP ACE app, and subscribe to RhAPPcast for future episodes.

  6. Jul 3

    RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 2

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Wendy Simmons, PA-C, for Part 2 of the EULAR 2026 Osteoporosis RhAPP Up Series. Together, they review key osteoporosis abstracts from the 2026 EULAR Congress, including new insights on the use of GLP-1 based therapies in patients taking oral bisphosphonates for osteoporosis and the potential impact on adverse events, medication tolerability, calcium absorption, and long-term bone health. This episode also explores bone mineral density in patients with rheumatoid arthritis under different biologic and targeted synthetic treatment strategies, highlighting the importance of ongoing bone health monitoring, individualized therapy decisions, and the need for additional research before applying these findings broadly in clinical practice. Stay tuned for the next episode in the EULAR 2026 Osteoporosis RhAPP Up Series. For more rheumatology education, visit the RhAPP Content Rheum and RhAPP ACE Mobile App.

  7. Jul 3

    RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 3

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Wendy Simmons, PA-C, for Part 3 of the EULAR 2026 Osteoporosis RhAPP Up Series. Together, they review key osteoporosis abstracts from the 2026 EULAR Congress, including new insights on the longitudinal impact of menopause on bone health and osteoporosis risk in women with spondyloarthritis, as well as the importance of monitoring bone mineral density, fracture risk, and individualized osteoporosis management. This episode also explores long-term data on romosozumab followed by denosumab compared with denosumab alone in glucocorticoid-induced osteoporosis, highlighting the value of treatment sequencing, anabolic-first strategies, trabecular bone score, and early intervention for patients at very high risk of fracture. Watch Part 3 now and revisit the full EULAR 2026 Osteoporosis RhAPP Up Series. For more rheumatology education, visit the RhAPP Content Rheum and RhAPP ACE Mobile App.

  8. Jul 1

    RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 1

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Wendy Simmons, PA-C, for Part 1 of the EULAR 2026 Osteoporosis RhAPP Up Series. Together, they review key osteoporosis abstracts from the 2026 EULAR Congress, including new insights on glucocorticoid-induced osteoporosis, adherence to the 2022 ACR guidelines, fracture risk reduction, and the role of rheumatology bone specialist clinics in improving patient outcomes. This episode also explores the treat-to-target approach in osteoporosis management, comparing real-world outcomes with teriparatide and denosumab, while highlighting the importance of individualized therapy, sequencing, bone mineral density goals, and early intervention for patients at high risk of fragility fractures. Watch Part 1 now and stay tuned for the next episodes in the EULAR 2026 Osteoporosis RhAPP Up Series. For more rheumatology education, visit the RhAPP Content Rheum and RhAPP ACE Mobile App.

See All (205)

Ratings & Reviews

5
out of 5
5 Ratings

About

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

Information

  • Creator
    Rheumatology Advanced Practice Providers (RhAPP)
  • Years Active
    2023 - 2026
  • Episodes
    205
  • Rating
    Clean
  • Copyright
    © 2025 RhAPPcast
  • Show Website
    RhAPPcast